Phase III PANORAMA trial of Eylea shows positive results in diabetic retinopathy.- Regeneron Pharma
Related news and insights
Regeneron Pharmaceuticals, Inc. announced the FDA as accepted for review the Eylea (aflibercept) Injection supplemental Biologics License Application (sBLA) for an every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR). The target action date for the FDA decision is February 28, 2023.
Regeneron announced JAMA Ophthalmology has published initial results from the National Institutes of Health-sponsored Protocol W trial assessing Eylea (aflibercept) Injection in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR), without center-involved diabetic macular edema (CI-DME).